Top-line results for SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® (SAXAGLIPTIN)
19 June 2013 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced top-line results...
List view / Grid view
19 June 2013 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced top-line results...
4 June 2013 | By Bristol-Myers Squibb Company
Metreleptin, an investigational agent for treatment of metabolic disorders associated with rare forms of LD...
2 June 2013 | By Bristol-Myers Squibb Company
Results from Study 004...
6 May 2013 | By Bristol-Myers Squibb Company
ARISTOTLE studied Eliquis vs. warfarin...
3 May 2013 | By Bristol-Myers Squibb Company
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
22 April 2013 | By Merck
Agreement to conduct a Phase II clinical trial evaluating combination of investigational oral candidates MK-5172 and daclatasvir for chronic hepatitis C...
7 April 2013 | By Bristol-Myers Squibb Company
The appointment of Francis Cuss announced...
14 February 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb announced that Ann Powell Judge will join the company...
12 February 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb has entered into an agreement with Reckitt Benckiser Group...
17 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb appoints Mike Burgess...
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
26 December 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb and Pfizer Inc. announced that the Japanese Ministry of Health, Labor and Welfare has approved ELIQUIS® (apixaban)...
12 December 2012 | By Bristol-Myers Squibb Company
Global license and two year collaboration for Recothrom®...
9 December 2012 | By Bristol-Myers Squibb Company
Results from Phase 2 open-label study...
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...